CABA
Cabaletta Bio Inc

3,613
Mkt Cap
$283.02M
Volume
8,441.00
52W High
$3.78
52W Low
$0.9857
PE Ratio
-1.16
CABA Fundamentals
Price
$2.94
Prev Close
$3.04
Open
$3.04
50D MA
$2.84
Beta
1.73
Avg. Volume
3.26M
EPS (Annual)
-$2.34
P/B
2.03
Rev/Employee
$0.00
$34.84
Loading...
Loading...
News
all
press releases
Cabaletta Bio (NASDAQ:CABA) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Cabaletta Bio (NASDAQ:CABA - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05...
MarketBeat·46m ago
News Placeholder
More News
News Placeholder
Cabaletta Bio (CABA) Projected to Post Earnings on Monday
Cabaletta Bio (NASDAQ:CABA) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-cabaletta-bio-inc-stock...
MarketBeat·6h ago
News Placeholder
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine brokerages that are currently covering the company, Marketbeat...
MarketBeat·4d ago
News Placeholder
Heights Capital Management Inc. Sells 1,059,904 Shares of Cabaletta Bio, Inc. $CABA
Heights Capital Management Inc. trimmed its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 33.7% during the third quarter, according to its most recent filing with the...
MarketBeat·5d ago
News Placeholder
Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference
Cabaletta Bio (NASDAQ:CABA) used a fireside chat at TD Cowen's 46th Annual Health Care Conference to highlight progress across its autoimmune cell therapy program, with executives emphasizing...
MarketBeat·16d ago
News Placeholder
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·17d ago
News Placeholder
Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday
Cabaletta Bio (NASDAQ:CABA) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...
MarketBeat·18d ago
News Placeholder
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Zacks·20d ago
News Placeholder
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of "Moderate Buy" by Brokerages
Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine brokerages that are covering the company, MarketBeat Ratings reports...
MarketBeat·29d ago
News Placeholder
Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA
Cabaletta Bio (NASDAQ:CABA) executives told investors at the Guggenheim Emerging Outlook Biotech Summit 2026 that the company has initiated enrollment in what it described as its first pivotal...
MarketBeat·1mo ago
<
1
2
...
>

Latest CABA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.